Informa Markets in India recently organised the CPHI & PMEC India 2023 at the India Expo Centre in Greater Noida, Delhi-NCR.
A statement from Informa markets informed, “As the largest and most exhaustive pharma industry gathering in South Asia, CPHI and PMEC India expo, drew an overwhelming positive response, attracting over 48,000 attendees from 120+ countries in a vast 100,000 sq m exhibition space. This year’s turnout exceeded previous editions, with over 1,500 exhibitors – a notable increase from last year. As the central hub of the pharma industry, the CPHI and PMEC India expo continues to grow in influence and scale. Across three dynamic days, the event served as a crucible for industry collaboration, hosting over 25,000 impactful buyer-seller meetings, fostering partnerships, and amplifying industry advocacy.”
It added, “From domestic powerhouses like Dr Reddy’s and Biocon to global leaders like IMA and Fette, alongside rising stars like Piramal Pharma and Hetero Labs, CPHI & PMEC India Expo brought together a diverse range of notable exhibitors. Some of them such as Korber Pharma GmbH, Uhlmann India, Glenmark Lifesciences, Petals Engineers, Solara Active Pharma Science, Merck Life Science, Gufic Biosciences, Jubilant Pharmova etc joined for the first time to showcase cutting-edge products from AI-enhanced quality control to pioneering drug delivery systems and sustainable initiatives. “
The 16th edition of the event was supported by key industry associations, including Bulk Drug Manufacturing Association (BDMA), Federation of Pharma Entrepreneurs (FOPE); Karnataka Drugs and Pharmaceuticals Manufacturers’ Association (KDPMA), Organisation of Pharmaceutical Producers of India (OPPI), and PharmExcil, highlighting the collaborative spirit driving India’s pharma growth.
The event kicked off with an opening attended by industry leaders, including Dr Veeramani SV, Vice-Chairman, PHARMEXCIL; Harish Jain, President, FOPE; Raja Bhanu, Executive Director, PHARMEXCIL; Margaret Ma, President & CEO – Informa Markets Asia; Chris Eve, Executive Vice President – Informa Markets Asia; Adam Anderson, Executive Vice President – Pharma, Informa Markets; Yogesh Mudras, Managing Director, Informa Markets in India; Rahul Deshpande, Senior Group Director, Informa Markets in India; and Ranjith Paul, Group Director, Informa Markets in India.
The ‘India Pharma Week’, held alongside the CPHI & PMEC India Expo, comprised a series of events including the Pharma Leaders Golf; Pre-Connect Congress; Pharma Leaders Roundtable; Women in Pharma; Pharma Talks; and India Pharma Awards. The closed-door Pharma Leaders’ Roundtable underscored the importance of directing attention toward both incremental and revolutionary innovation. The discussions also addressed the significance of cost efficiency and digital transformation to optimise operations and curtail expenses. Other pivotal issues such as the innovation funding gap, need for strategic alliances with academia, biotech entities, and venture capital firms, establishment of innovation clusters to nurture collaboration and facilitate the exchange of knowledge were also discussed. Informa markets informed that a white paper report on the key takeaways is being prepared.
Highlighting India’s promising position within the global market, Yogesh Mudras, Managing Director, Informa Markets in India said, “India has earned its way to becoming a pharma super power with over 200+ countries served by Indian pharma exports. And yet, obstacles remain with nearly 30 per cent of Indians lacking access to medicines. We are truly at an inflection point where we are finding innovative ways for seamless Geographical distribution of pharmaceutical access of quality supply.”
“For 16 years, CPHI & PMEC India has been at the pulse of the pharma industry’s meteoric rise, evolving from a trade show to a global hub for innovation and collaboration. We proudly represent the world’s largest pharma community, fueling India’s domestic muscle, surging R&D, and government support. This remarkable growth is driven by cutting-edge technology, breakthrough drugs, and a patient-centric focus, positioning India as a major player in the global pharma landscape. CPHI & PMEC India remains dedicated to playing a vital role in India’s journey towards pharma excellence through its platforms enabling collaboration, knowledge sharing, and innovation,” he added.